Show simple item record

dc.contributor.authorAhrens, M.
dc.contributor.authorEscudier, B.
dc.contributor.authorHaanen, J.
dc.contributor.authorBoleti, E.
dc.contributor.authorGross-Goupil, M.
dc.contributor.authorGrimm, M. O.
dc.contributor.authorNegrier, S.
dc.contributor.authorBarthelemy, P.
dc.contributor.authorGravis, G.
dc.contributor.authorIvanyi, P.
dc.contributor.authorBedke, J.
dc.contributor.authorCastellano, D.
dc.contributor.authorPanic, A.
dc.contributor.authorMellado, B.
dc.contributor.authorMaroto, P.
dc.contributor.authorRottey, S.
dc.contributor.authorZschabitz, S.
dc.contributor.authorFlorcken, A.
dc.contributor.authorBogemann, M.
dc.contributor.authorWaddell, Thomas
dc.contributor.authorRodriguez, C. S.
dc.contributor.authorLorch, A.
dc.contributor.authorDeckbar, D.
dc.contributor.authorHartmann, A.
dc.contributor.authorBergmann, L.
dc.date.accessioned2023-01-16T14:12:59Z
dc.date.available2023-01-16T14:12:59Z
dc.date.issued2022en
dc.identifier.citationAhrens M, Escudier B, Haanen J, Boleti E, Gross-Goupil M, Grimm MO, et al. An ongoing, randomized phase II study of Nivolumab plus Ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST). Oncology Research and Treatment. 2022 Nov;45(SUPPL 3):101-2. PubMed PMID: WOS:000883051700235.en
dc.identifier.urihttp://hdl.handle.net/10541/625908
dc.language.isoenen
dc.titleAn ongoing, randomized phase II study of Nivolumab plus Ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentUniversity Hospital Frankfurt, Medical Clinic II, Hematology and Oncology, Frankfurt, Deutschlanden
dc.identifier.journalOncology Research and Treatmenten
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record